Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01696058 · ClinicalTrials.gov registry record · Phase 3
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,137
- Enrollment target
NCT01696058 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,137 participants.
The verdict
NCT01696058, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,137 participants
- Enrollment target
Study Summary
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.
Interventions
- DRUG Tiotropium
- DRUG Olodaterol
- DRUG Placebo matching Olodaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,137 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01696058
The ClinicalTrials.gov registry entry for NCT01696058 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tiotropium is the first listed.
NCT01696058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01696058 about?
NCT01696058 is a clinical study titled "Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®". The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) mo...
What is the current status of trial NCT01696058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,137 participants. The study started on 2012-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01696058?
The interventions under investigation include: Tiotropium (DRUG), Olodaterol (DRUG), Placebo matching Olodaterol (DRUG).
Who is sponsoring clinical trial NCT01696058?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.